fbpx

Lyfebulb and UnitedHealth Group Announce The Winner of Their 2019 Innovation Challenge for Patient Entrepreneurs

Challenge brought together 10 finalists who are building solutions for those affected by depression and anxiety

MINNETONKA, Minn., and NEW YORK (July 24, 2019) Lyfebulb LLC and UnitedHealth Group (NYSE: UNH) are pleased to announce that Rohan Dixit of Lief Therapeutics was selected as the winner of the “Addressing Unmet Needs in Depression & Anxiety: An Innovation Challenge.” Lief Therapeutics has developed an intuitive, data-driven wearable consumer product for anxiety used to teach the skill of mindfulness using heart rate variability.

Rohan was selected from a group of passionate innovators who were finalists in the Challenge, including Jay Brown of Health Behavior Solutions; Matt Loper of Wellth; Lisa McLaughlin of Workit Health; Katherine Ponte of ForLikeMinds; Jan Samzelius of NeuraMetrix; Dr. Ryan Stoll of COMPASS for Courage; Dr. Mehran Talebinejad of NeuroQore; Quayce Thomas of Timsle; and Keith Wakeman of SuperBetter.

Dennis Urbaniak, Chief Digital Officer of Havas Health & You, who served as Chair of the Jury commented, “Rohan not only has a mission and purpose that aligned with the criteria of the challenge, but also has taken a conventional approach and reimagined it through the patient experience with evidence-based science behind it. Additionally, he has identified viable pathways to commercialization.”

The Innovation Challenge was open to established companies of all sizes that are founded or led by an entrepreneur who has been affected by depression and anxiety, whether as a patient or through a loved one, and who has created a product or service to address an unmet need identified through personal experience. The 10 finalists gathered at UnitedHealth Group’s headquarters for two days of meetings, workshops and pitch presentations. The event culminated with a panel of esteemed judges selecting Rohan Dixit for the $25,000 award.

“Partnering with UnitedHealth Group for a second year in a new therapeutic area which impacts all of healthcare is tremendous for Lyfebulb,” said Dr. Karin Hehenberger, Founder and CEO of Lyfebulb. “We have established a community of people affected by and caring about depression and anxiety, from which we sourced ten exceptional patient entrepreneurs to join us in Minnetonka over the past few days. Their passion and determination to solve daily issues that burden so many individuals came through clearly during the pitches.”

The judges included experts from the patient, business and medical communities including Mike Christy, Senior Vice President of Venture Development at UnitedHealth Group; Dr. Raja M. David, Founder and Owner of Minnesota Center for Collaborative/Therapeutic Assessment; Matt Kudish, Executive Director at NAMI-NYC (National Association of Mental Illness); AnnMarie Otis, Patient Advocate; Dr. Bethany Ranes, Research Associate at UnitedHealth Group; and Dennis Urbaniak, Chief Digital Officer at Havas Health & You.

“Through this innovation challenge, we learned from patients and caretakers who live and breathe the challenges of this disease every day,” said Dr. Deneen Vojta, Executive Vice President and Chief Medical Officer of Research & Development at UnitedHealth Group.  “We see depression and anxiety touch all populations we serve and we valued the opportunity to bring together entrepreneurs, health care providers, patient advocates and business leaders at the summit. Together, we can help bring the most innovative, effective tools – inspired by personal experiences – into the marketplace.”

Lyfebulb and UnitedHealth Group Launch Second Annual Innovation Challenge for Patient Entrepreneurs

Lyfebulb and UnitedHealth Group Launch Second Annual Innovation Challenge for Patient Entrepreneurs

  • Challenge aims to inspire patient-driven innovation in the management of depression and anxiety
  • Finalists will compete at UnitedHealth Group headquarters for a chance to win $25,000

group image for UnitedHealth Innovation Challenge

MINNETONKA, Minn. and NEW YORK, May 13, 2019 /PRNewswire/ Lyfebulb LLC and UnitedHealth Group (NYSE: UNH) invite patient entrepreneurs to compete in “Empowering Patients: An Innovation Challenge,” for the second annual Lyfebulb and UnitedHealth Group Innovation Award.

This year’s challenge will recognize the top patient entrepreneurs developing innovative ideas for better management of depression and anxiety using health care information technology, medical devices, diagnostics, consumer products or services.

UnitedHealth Grouup logo

Eligible companies are those that are founded or led by a patient entrepreneur: someone who has been personally affected by depression or anxiety (themselves or through a loved one) and who develops a product or service to address an unmet need identified through personal experience. Companies based in the United States or Canada (excluding Quebec) are eligible to apply. The application, detailed rules and eligibility criteria can be found at click here. Applications are open until 11:59pm EST on May 31, 2019.

“Depression and anxiety are issues that particularly affect people living with chronic disease,” said Dr. Karin Hehenberger, founder and CEO of Lyfebulb. “We are honored to work with UnitedHealth Group on an issue that affects so many people in our community and nationwide. We are eager to tap into the unique insights that patients have, and leverage those to identify user-driven solutions by patient entrepreneurs for issues they face.”

A joint steering committee composed of Lyfebulb and UnitedHealth Group executives will conduct a thorough sourcing and screening process, and select 10 finalists who will be invited to the Empowering Patients event July 23-24, 2019, at UnitedHealth Group’s headquarters in Minnetonka. There, the finalists will pitch their solutions to a panel of experts (a jury) from the business, medical and patient communities. The jury will award a $25,000 prize to the company with the most innovative and impactful solution at the closing ceremony.

“Depression and anxiety weave through all areas of disease – chronic and acute – yet they are understudied and underserved in terms of dialogue and solutions today in the United States,” said Gene Baker, Ph.D., a research fellow at UnitedHealth Group. “We are grateful for the opportunity to partner with Lyfebulb and look forward to hearing from patients and entrepreneurs to learn more about the innovative, patient-driven solutions to help people living with depression and chronic disease.”

About Lyfebulb
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry (manufacturers and payers) to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis and depression/anxiety.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a diversified health care company dedicated to helping people live healthier lives and helping to make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.

Contact:

Lyfebulb
Karin Hehenberger, M.D., Ph.D., CEO
917-575-0210; Karin@lyfebulb.com

UnitedHealth Group
Tyler Mason
424-333-6122, tyler.mason@uhg.com

Lyfebulb Partners with UnitedHealth Group to Support Patient-Driven Innovations for People with Inflammatory Bowel Disease

NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE) — Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients, industry and investors to support user-driven innovation, is partnering with UnitedHealth Group (NYSE:UNH) to launch an innovation challenge featuring new businesses and products aimed at treating inflammatory bowel disease (IBD).

According to the Centers of Disease Control and Prevention, up to 1.3 million people in the United States are affected by IBD, which includes Crohn’s disease (CD) and ulcerative colitis (UC). Lyfebulb and UnitedHealth Group will help raise awareness for the conditions and stimulate user-driven innovation. By linking entrepreneurs with representatives from UnitedHealth Group and Lyfebulb, the partnership will spotlight the entrepreneurs’ efforts and ideas, and provide professional discussion, direction and inspiration.

The innovation challenge, to take place in the spring and summer of 2018, will be open to entrepreneurs living with IBD, or who have family members living with IBD, who have founded a company to develop an innovative idea for better management of IBD using pharmaceuticals, biotechnology, medical devices or consumer products. Eligibility criteria and official rules will be announced by Lyfebulb in April. UnitedHealth Group will host an innovation event in July for 10 finalists. A panel of judges will award cash prizes to three winners, to be used for their company’s further development of the winning innovations.

“Patients living with chronic disease and caregivers caring for someone with chronic disease understand the many challenges they face and are often in the best position to offer tangible solutions,” said Deneen Vojta, M.D., executive vice president, Research & Development, UnitedHealth Group. “UnitedHealth Group’s partnership with Lyfebulb will help place the patient at the center of early-stage innovation, thus providing us a unique opportunity to learn from and be inspired by patient-entrepreneurs.”

“This partnership with UnitedHealth Group in IBD means a tremendous amount to Lyfebulb in our efforts to enhance patient-driven innovation,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Continuing to build on the concept of patient entrepreneurs and partnering with leaders across health care are key components to fulfilling our mission to improve the quality of life of people living with chronic disease.”

Press Contact for Lyfebulb:
Karin Hehenberger, MD, PhD, CEO Lyfebulb, phone: 917-575-0210 email: karin@lyfebulb.com

About Lyfebulb
Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and IBD.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About UnitedHealth Group
UnitedHealth Group (NYSE:UNH) is a diversified health and well-being company dedicated to helping people live healthier lives and helping make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.

Press Contact for UnitedHealth Group:
Jim Merwin, Senior Director, ERD, phone: 952-936-6070, to email: james_merwin@uhg.com

Interests - Select all that apply